We Value Partnerships! Current Oncology is pleased to highlight the valuable partnerships we have with the following organizations: 1) Oncology Educ

CO-NEWSLETTER-LOGO Feb2014

We Value Partnerships!

Current Oncology is pleased to highlight the valuable partnerships we have with the following organizations:

1) Oncology Education

2) The Cardiovascular and Interventional Radiological Society of Europe (CIRSE)

Copies of Current Oncology will be available at our partner’s conferences. Find out which ones below:

Oncology Education – “Best of Oncology 2014 West Conference” – February 28th, 2014 in Vancouver, BC
CIRSE – “Firth European Conference on Interventional Oncology” – April 23rd-26th, 2014 in Berlin, Germany

Look for our partner’s advertisements in the print issue of Volume 21, Number 1 (February 2014) for more information about upcoming conferences!

Why partner with Current Oncology?

Current Oncology is your premier partner for reaching a diverse, growing community of engaged and knowledgeable oncologists, specialists in allied disciplines, residents, nurses, family physicians, and patients and their families throughout Canada. Current Oncology draws the attention of these professionals and the interested public because of its combination of integrity, credibility, and high-value content as exemplified in:

• an editorial board that includes some of the most respected researchers, authors, teachers, and practitioners in the field;
• status as the only peer-reviewed journal covering Canadian oncologic practice in addition to reports and reviews of studies and primary research of global significance;
• a consistently high quality of submissions, leading to acceptance of the journal for indexing in the U.S. National Library of Medicine’s PubMed database, PubMed Central, and Excerpta Medica, among others; and
• Impact factor of 1.625, as published in the 2012 Journal Citation Reports, Science Edition (Thomson Reuters, 2013).

Current Oncology offers a variety of possibilities for disseminating your message; developing relationships with the research, practice, or patient communities; or publishing your own innovations and discoveries.

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
CO Twitter Banner Ad
***
InPress-CON

Volume 21, Number 1 (February 2014)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

***
LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 21, Number 2 (April 2014) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

***
EditorSpotlight
RD Bonfil

Dr. R. Daniel Bonfil, Ph.D.
Editor of our Oncologic Pathology Section (since January 2009)

Dr. R. Daniel Bonfil is Associate Professor of Urology, Pathology, and Oncology at Wayne State University School of Medicine, and Scientific Member of Karmanos Cancer Institute, Detroit, MI.

Dr. Bonfil was born in Buenos Aires, Argentina, where he obtained his M.Sc. and Ph.D. degrees in Biological Sciences from the University of Buenos Aires. He did postdoctoral training in Cancer Biology in the Department of Pathology at Fox Chase Cancer Center, Philadelphia, PA. Prior to moving to his current position in the United States in 2002, he was investigator with tenure of the National
Council for Scientific and Technological Research, head of the Experimental Oncology at the National Academy of Medicine, and president of the Cancer Research Foundation, in Argentina. He has authored 80 scientific manuscripts, and several book chapters.

Dr. Bonfil’s research focuses on molecular and cellular mechanisms leading to the development of bone metastasis in prostate cancer

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (January 2014)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C.
Curr Oncol. 2010 Aug;17(4):94-112

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M
Curr Oncol. 2009 Jan;16(1):16-26

Most Read Recently* Published Articles at www.current-oncology.com

Genetically modified foods, cancer, and diet: myths and reality
Touyz L.Z.G.
Curr Oncol. 2013 Apr; 20(2):e59-e61

Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
H. Kennecke, L. Chen, C.D. Blanke, W.Y. Cheung, K. Schaff, C. Speers
Curr Oncol. 2013 Dec; 20(6):326-332

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer
Morgillo F., De Vita F., Antoniol G., Orditura M., Auriemma P.P., Diadema M.R., Lieto E., Savastano B., Festino L., Laterza M.M., Fabozzi A., Ventriglia J., Petrillo A., Ciardiello F., Barbarisi A., Iovino F.
Curr Oncol. 2013 Aug; 20(4):e283-e288

*Published within past 12 months

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px